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AbstrACt
Objectives To describe the construction of the 
international INTERGROWTH- 21st Neurodevelopment 
Assessment (INTER- NDA) standards for child development 
at 2 years by reporting the cognitive, language, motor and 
behaviour outcomes in optimally healthy and nourished 
children in the INTERGROWTH-21st Project.
Design Population- based cohort study, the 
INTERGROWTH- 21st Project.
setting Brazil, India, Italy, Kenya and the UK.
Participants 1181 children prospectively recruited from 
early fetal life according to the prescriptive WHO approach, 
and confirmed to be at low risk of adverse perinatal and 
postnatal outcomes.
Primary measures Scaled INTER- NDA domain scores 
for cognition, language, fine and gross motor skills and 
behaviour; vision outcomes measured on the Cardiff tests; 
attentional problems and emotional reactivity measured on 
the respective subscales of the preschool Child Behaviour 
Checklist; and the age of acquisition of the WHO gross 
motor milestones.
results Scaled INTER- NDA domain scores are presented 
as centiles, which were constructed according to the 
prescriptive WHO approach and excluded children born 
preterm and those with significant postnatal/neurological 
morbidity. For all domains, except negative behaviour, 
higher scores reflect better outcomes and the threshold 
for normality was defined as ≥10th centile. For the INTER- 
NDA’s cognitive, fine motor, gross motor, language and 
positive behaviour domains these are ≥38.5, ≥25.7, ≥51.7, 
≥17.8 and ≥51.4, respectively. The threshold for normality 
for the INTER- NDA’s negative behaviour domain is ≤50.0, 
that is, ≤90th centile. At 22–30 months of age, the cohort 
overlapped with the WHO motor milestone centiles, 
showed low postnatal morbidity (<10%), and vision 
outcomes, attentional problems and emotional reactivity 
scores within the respective normative ranges.
Conclusions From this large, healthy and well- nourished, 
international cohort, we have constructed, using the 
WHO prescriptive methodology, international INTER- 
NDA standards for child development at 2 years of age. 
Standards, rather than references, are recommended 
for population- level screening and the identification of 
children at risk of adverse outcomes.
strengths and limitations of this study
 ► The prescriptive WHO approach for developing bio-
logical standards was applied to a population- based 
sample of healthy and well- nourished children from 
Brazil, India, Italy, Kenya and the UK to construct 
the INTERGROWTH-21st Project neurodevelopmen-
tal assessment (INTER- NDA) standards for child 
development.
 ► Comprehensive health, growth and neurodevelop-
mental data were prospectively collected, from early 
pregnancy to 2 years postbirth, providing a unique 
opportunity to confirm the cohort’s health and nutri-
tional status and to control for multiple risk factors 
associated with suboptimal child development.
 ► The INTER- NDA is a mixed- methodology, multi-
dimensional, standardised measure of early child 
development, which can be administered rapidly, by 
non- specialists in high- income, middle- income and 
low- income settings.
 ► The INTER- NDA is a standardised screening assess-
ment and does not provide a clinical diagnosis.
 ► The age range of the INTER- NDA is 22–30 months 
and limits its generalisability to other age groups.
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IntrODuCtIOn
Approximately 250 million children under the age of 5 
worldwide are at risk of not achieving their developmental 
potential.1 Effective interventions are available but maxi-
mising their benefit at scale depends on identifying those 
children at greatest need, preferably using standardised 
methodology.2
At present, a multiplicity of methods is used to measure 
neurodevelopment during early childhood (online 
supplementary information S1).3 4 Many of these are 
administered by specialist staff and were developed using 
children from either high- income countries or specific 
low- income and middle- income countries, each drawing 
their normative sample (often country or region specific) 
from the respective settings (online supplementary infor-
mation S1 and S2).3 4 To our knowledge, none of these 
tools commonly used to measure neurodevelopment in 
early childhood, were based on children monitored from 
fetal life and have adopted the prescriptive approach 
recommended by the WHO for the development of inter-
national biological standards during the construction of 
their norms.5 Instead, references have been commonly 
used to assess the overall achievement of developmental 
skills and track progress over time in both, groups of chil-
dren and individuals. However, while references describe 
how children, in a specific setting and time, have attained 
certain milestones of interest, they do not describe how 
children, in all settings, should develop. The importance of 
this fundamental difference between references and stan-
dards was elegantly highlighted, in the context of skeletal 
growth in young children, by WHO Multicentre Growth 
Reference Study (MGRS), which resulted in the construc-
tion of prescriptive international standards for moni-
toring child growth.6 These WHO standards, describing 
optimal growth from early pregnancy to 5 years of age,7 
are now widely employed in clinical practice and used to 
make comparisons across disparate populations.
The construction of international, prescriptive stan-
dards describing optimal neurodevelopment during early 
childhood is challenging not least because of the tech-
nical and logistical difficulties of implementing compre-
hensive early child developmental assessments across 
large international populations. To construct interna-
tional standards of child development, in accordance with 
WHO’s prescriptive methodology,5 four fundamental 
methodological principles must be fulfilled: (1) the 
normative sample should be selected using a ‘prescrip-
tive’ approach, which includes consideration of key 
factors known to be associated with poor developmental 
outcomes during early childhood (online supplementary 
information S2); (2) the conceptual framework must be 
population- based and international; (3) rigorous data 
management, standardisation and quality control proce-
dures must be included and (4) measurements must be 
complemented by independent assessments of specific 
functional and developmental domains (eg, tests of 
vision) to confirm the prescriptive characteristics of the 
sample. This rigorous approach is important because the 
inclusion of inadequately nourished children, or those 
with mild neurodevelopmental disturbances (NDDs), in 
normative samples, can affect resultant thresholds. More-
over, the identification of children at risk of (even mild) 
NDDs is essential because there is evidence to show that 
very small developmental differences between individuals 
during early childhood can result in marked discrepan-
cies in mental and physical health, educational attain-
ment, and social and economic outcomes during later 
life.8 9
The INTERGROWTH-21st Project aimed to adopt 
this WHO prescriptive approach in constructing inter-
national standards for child development measured 
on a standardised, comprehensive assessment tool—
the INTERGROWTH-21st Neurodevelopment Assess-
ment (INTER- NDA)—at 2 years of age. Despite this 
circumscribed age range, by leveraging on the INTER-
GROWTH-21st Project’s international cohort of mothers 
and children, recruited specifically to be optimally 
healthy and well- nourished throughout the duration of 
pregnancy and confirmed, during the infant follow- up 
component of the project, to be at low risk of adverse 
birth, health and growth outcomes at birth, 1 and 2 years 
of age, we were able to adopt the prescriptive approach 
and methods recommended by the WHO MGRS in the 
construction of the INTER- NDA standards of child devel-
opment at 2 years of age. In the present study, we anal-
ysed cognitive, language, motor and behaviour outcomes 
at 2 years of age, measured on the INTER- NDA, for 
healthy and well- nourished children from the INTER-
GROWTH-21st Project study sites in Brazil, India, Italy, 
Kenya and the UK. We compared the vision, gross motor, 
attentional problems and emotional reactivity profiles, 
as well as growth and health outcomes, in these chil-
dren to the corresponding norms for these independent 
measures.
MethODs
study design and population
The INTERGROWTH-21st Project was a multicentre, 
population- based study conducted between 2009 and 
2016, in eight delimited geographical areas worldwide: 
the cities of Pelotas, Brazil; Turin, Italy; Muscat, Oman; 
Oxford, UK; Seattle, USA; Shunyi County, a suburban 
district of the Beijing municipality, China; the central 
area of the city of Nagpur, Maharashtra, India and the 
Parklands suburb of Nairobi, Kenya. A geographical area 
was a complete city, or county, or part of a city with clear 
political or geographical limits, located at an altitude 
<1600 m, with low- risk health indicators for perinatal 
morbidity and mortality, in which women receiving ante-
natal care had plans to give birth within the area, that 
had to be free or have low levels of major, known, non- 
microbiological contamination.10 The primary aim of 
the INTERGROWTH-21st Project was to study growth, 
health and development from early fetal life to 2 years of 
age in low- risk populations of mothers and children with 
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optimal health and nutrition so as to produce prescriptive 
standards of fetal growth, newborn size and early child 
neurodevelopment to complement the existing WHO 
Child Growth Standards.
The INTERGROWTH-21st Project recruited pregnant 
women from the aforementioned populations, who met 
the individual entry criteria of health, nutrition, educa-
tion and socioeconomic position (online supplemen-
tary information S3).10 Standardised clinical care and 
neonatal feeding practices were implemented based on 
project protocols. The newborn cohort was followed up at 
birth, 1 and 2 years of age and evaluated for growth, nutri-
tion, health and the WHO gross motor milestones, using 
standardised methodology and rigorous quality control 
processes.11 They constitute the Infant Follow- up Study 
(IFS) of the INTERGROWTH-21st Project. The baseline 
characteristics of the full cohort and follow- up meth-
odology have been published elsewhere.11 The project 
protocols are available at www. intergrowth21. org. uk.
Data collection and evaluation methods
All eligible children in five of the eight INTER-
GROWTH-21st Project study sites (the cities of Pelotas 
(Brazil); Turin (Italy); Oxford (UK); Nagpur (India) 
and the Parklands suburb of Nairobi (Kenya)), who had 
contributed data towards the construction of the interna-
tional Fetal Growth and Newborn Growth Standards,12 13 
were invited to attend a comprehensive neurodevelop-
mental evaluation at the time of their second birthday. 
This age was selected as it was found to be the earliest 
at which: (1) neurodevelopment is not confounded by 
transient neurological syndromes of prematurity and (2) 
conventionally used developmental instruments, such as 
the Bayley Scales of Infant Development (BSID), have 
been found to possess an acceptable level of medium 
and long- term predictive validity.14 The sites in China, 
Oman and the USA did not participate because of logis-
tical and administrative reasons, delays in the start of the 
study and/or staff availability, all unrelated to the IFS’ 
main hypotheses (a comparison in the demographics, 
and health and growth outcomes between these sites has 
already been published).11
The evaluation consisted of (in order of adminis-
tration): an assessment of vision (the Cardiff tests) an 
assessment of cognition, motor skills, language skills 
and behaviour (the INTER- NDA); caregiver reports of 
attentional problems and emotional reactivity (the corre-
sponding subscales of the preschool Child Behaviour 
Checklist; CBCL); measurement of cortical auditory 
processing (to a novelty odd- ball paradigm on a wireless, 
gel- free electroencephalography system); measurement 
of infant sleep (using actigraphy) and an assessment of 
gross motor milestones (based on the WHO’s checklist). 
Despite measuring cortical auditory processing and sleep 
in our cohort, a description of the methods and results 
relating to these technically complex outcomes are 
beyond the scope of this paper. Moreover, as normative 
values for cortical auditory evoked response potentials 
and actigraphy data do not exist for children aged 2 
years, the added value of these measures in confirming 
the healthy and well- nourished status of the cohort is 
uncertain. Information on the child’s health and nutri-
tional status, and anthropometric measurements (weight, 
length and head circumference), were also collected, at 
the 2 year visit, according to the INTERGROWTH-21st 
Project protocols.
A specially designed training programme for the neuro-
developmental evaluation was implemented at all sites 
between 2012 and 2013.15 Staff administering the assess-
ments were aware of the project’s general principles but 
not the specific hypotheses being tested. They were also 
unaware of individual children’s scores from their own 
and other study sites.
Primary outcome measure: the Inter-nDA
The INTER- NDA is a comprehensive, rapid assessment 
of cognition, (fine and gross) motor skills, language 
and (positive and negative) behaviour for children aged 
22–30 months (online supplementary information S4).15 
Its 37 items are administered in approximately 15 min 
using a combination of psychometric techniques (direct 
administration, concurrent observation and caregiver 
reports) to minimise risks of reporter and recall bias 
commonly encountered in caregiver interviews3 while 
acknowledging that children might perform differently 
in artificial testing environments than in familiar settings. 
Children’s performance on the INTER- NDA is scored 
across a spectrum of abilities, rather than on a predefined 
checklist and, therefore, affords a wider description of a 
child’s faculties.15 It has demonstrated strong agreement 
with the BSID, third edition (BSID- III) (interclass correla-
tion coefficients 0·75–0·88, p<0·001 for all domains with 
little to no bias on Bland Altman analysis); satisfactory 
internal consistency (Cronbach’s alpha 0.56–0.81) and 
good unidimensionality across subscales (Comparative 
Fit Index=0.90; Tucker- Lewis Index=0 .94)16 and good 
levels of inter- rater (k=0·70; 95% CI 0·47 to 0·88) and 
test–retest reliability (k=0·79; 95% CI 0·48 to 0·96).15
The INTER- NDA is designed for use across socioeco-
nomic groups and populations. Its operation manual, 
standardisation protocol and forms are freely available at 
www. intergrowth21. org. uk. The kit consists of common 
household items encountered across the world. In all 
study sites, the INTER- NDA was translated into the local 
languages of the sites (Brazil: Brazilian Portuguese, India: 
Marathi; Italy: Italian; Kenya: Kiswahili), using the WHO 
Mental Health Initiative translation guidelines,17 which 
included processes of cultural customisation, translation 
and back translation.
Other outcome measures of neurodevelopment
To confirm the developmental normality of our cohort, 
we assessed specific functional and developmental 
outcomes of relevance by including three measurements 
independent of the INTER- NDA: (1) visual acuity and 
contrast sensitivity, measured on the Cardiff Tests18; (2) 
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attention problems and emotional reactivity measured 
on the respective subscales of the preschool CBCL19 and 
(3) the age of achievement of six gross motor milestones 
measured on the WHO’s checklist.20
The Cardiff Tests are validated and reliable measures 
of binocular vision in children that are not influenced by 
coexisting disturbances in language or cognition, and are 
independent of cultural biases. Their norms have been 
applied for clinical purposes.18 The operational manual 
for their use in the INTERGROWTH-21st Project is avail-
able at https://www. intergrowth21. org. uk. Their admin-
istration takes 5 min. Visual acuity and contrast sensitivity 
are measured in quick succession and taken together are 
a more robust measure of the integrity and functioning of 
the entire visual pathway than either test alone.21
The preschool version of the CBCL is a parent- rated 
questionnaire used worldwide as a diagnostic screen for 
behavioural and emotional problems in young children 
(https:// aseba. org/ translations/).19 In the IFS of the 
INTERGROWTH-21st Project, mothers completed ques-
tions relating to the attentional problems and emotional 
reactivity CBCL scales.
The WHO Gross Motor milestones checklist consists 
of the normative windows of achievement for six gross 
motor milestones, developed from the WHO MGRS 
cohort between 4 and 24 months of age.20 In the INTER-
GROWTH-21st Project, parents were asked to report the 
age when they first observed or ‘never observed’ the mile-
stones. The same information was collected from parents 
at the 1- year and 2- year follow- up visits to evaluate the 
consistency of the reported dates.11
Data management and statistics
The INTERGROWTH-21st Project neurodevelopmental 
evaluation was supported by an electronic, tablet- 
based data collection and management system (the 
NeuroApp).15 This contained the INTER- NDA and vision 
scoring forms, operation manuals, visual cues and inte-
grated data quality checks to facilitate rapid collection of 
high- quality data and to ensure their secure upload to the 
project’s centralised and site- based data servers on which 
rigorous monthly checks were performed.22
For the INTER- NDA, two standardisation evaluations 
were carried out, in accordance with guidelines published 
in the World Bank’s Toolkit for Examining Early Child 
Development,3 to assess the ability of assessors to score and 
administer the INTER- NDA. During the first evaluation, 
assessors scored children’s skills on the INTER- NDA from 
video recordings of four assessments performed by an 
expert assessor. Inter- rater and test–retest reliability were 
compared between assessors. At the second evaluation, an 
expert observed assessors performing three assessments 
each, and rated each assessor for their ability to admin-
ister the INTER- NDA correctly on a standardised protocol 
adherence checklist (online supplementary information 
S5). Protocol adherence scores were compared between 
assessors. The results of these evaluations are presented 
in online supplementary information S6.
The sample size considerations for this report have 
been previously published and depended on pragmatic 
considerations.23 In summary, as the present report is the 
2- year follow- up of the initial FGLS cohort of pregnant 
women, the total number of eligible children assessed at 
2 years of age was therefore fixed. The initial sample size 
estimations (approximately 500 fetuses per site) focused 
on the precision and accuracy of the extreme centiles of 
the complete population, that is, the 3rd or 97th centile 
because they correspond closely to ±2 SD, and they are 
the recommended cut- offs of the WHO Child Growth 
Standards, which are used internationally to evaluate chil-
dren of this age; however, in the present study, such esti-
mations do not apply because of the different nature of 
the hypothesis.23 In this component of the study, neuro-
development was evaluated in an average of 261 children 
per site (1307 children total) at 2 years of age. This sample 
size was considered adequate to explore the predicted 
small site- specific differences. Post hoc power calculations 
showed that the study was sufficiently powered to observe 
small differences among study sites (calculations for 
INTER- NDA domains with power >0.99) and small effect 
sizes for the between- group variances.23 For example, for 
a between- group variance of 10% of the total variance 
and a two- tail alpha of 0.05, the power is 0.84.
Summary statistics were calculated for birth, neonatal 
and postnatal characteristics of children completing 
the neurodevelopmental evaluation and compared with 
those lost to follow- up. These characteristics include most 
factors associated with poor child neurodevelopmental 
outcomes during the first 2 years of life (online supple-
mentary information S2). The analytical and statistical 
strategy for the construction of the INTER- NDA centiles 
is presented in figure 1. For all analyses, Stata V.15 soft-
ware was used (StataCorp).
Data from the participating sites were pooled, following 
the strategy recommended by WHO.7 We have previ-
ously reported striking similarities in the distribution of 
the INTER- NDA domains among children from the five 
sites.23 In summary, similar to the patterns observed in 
linear growth from fetal life to childhood, the variability 
in INTER- NDA scores between sites is far less (for most 
domains <10%) than the total variability between indi-
viduals within a study site, justifying pooling the data to 
construct international standards.23 24
Raw mean INTER- NDA domain scores (online supple-
mentary information S716) were calculated and their 
distributions explored. These showed important skewness 
and (particularly) kurtosis. As 30 INTER- NDA items were 
scored on a five- point scale, and six items were scored on 
a three- point scale, raw domain scores were converted to 
standardised scaled scores (online supplementary infor-
mation S8).
To explore the low- risk profile of the cohort, centiles 
for visual acuity (measured in logMAR) and contrast 
sensitivity (measured in contrast per cent) were deter-
mined and compared with the Cardiff Tests’ established 
norms.18 Attention problem and emotional reactivity 
5Fernandes M, et al. BMJ Open 2020;10:e035258. doi:10.1136/bmjopen-2019-035258
Open access
Figure 1 Analytical and statistical strategy for the 
construction of the International INTERGROWTH-21st Project 
INTER- NDA standards. INTER- NDA, INTERGROWTH-21st 
Neurodevelopment Assessment.
Figure 2 Participant flow for the INTERGROWTH-21st 
Project Infant Follow- up Study cohort at 2 years of age. 
CBCL, Child Behaviour Checklist; FGLS, Fetal Growth 
Longitudinal Study; INTER- NDA, INTERGROWTH-21st 
Neurodevelopment Assessment.
subscale scores were calculated using ASEBA- web soft-
ware, and compared with the CBCL’s norms for group 1 
societies.19 The proportion of children within the WHO 
motor development windows of achievement was esti-
mated as previously described.11
In addition, after other exclusions (figure 2), 28 of 
1209 eligible children scored above the CBCL’s 97th 
percentile threshold for clinical problems on the atten-
tional problems and emotional reactivity CBCL subscales. 
We compared INTER- NDA centiles including and 
excluding this group (online supplementary informa-
tion S9). As the INTER- NDA centiles were marginally 
lower on some domains when this group was included, 
we decided to exclude these children from the normative 
sample INTER- NDA sample in the construction of the 
INTER- NDA domain standards.
As no transformation was identified that suited all 
INTER- NDA domains, the Harrell- Davis distribution- free 
estimator was used to estimate pooled centiles from the 
standardised scaled scores.25 This estimator weights the 
order statistics by the difference between two incomplete 
beta functions. INTER- NDA scaled domain scores were 
compared between boys and girls using the Wilcoxon 
rank- sum test.
Patient and public involvement
Patients were not involved in developing plans for the 
design of the study. Parents showed support for the 
study through high and sustained follow- up rates in all 
study sites. The INTERGROWTH-21st Project maintains 
contact with parents in the cohort through newsletters, 
webinars and blogs on its website, https:// intergrowth21. 
tghn. org/ and through Twitter (@intergrowth21st).
results
the InterGrOWth-21st Project IFs study: Inter-nDA 
normative cohort characteristics and overall health and 
nutrition at 2 years of age
Population
Of the 1758 eligible children enrolled in the five partic-
ipating sites, 1339 (76%) were assessed at 2 years of 
age (figure 2). After exclusions (including 54 children 
(3.1%) who were born at <37+0 weeks’ gestation and 28 
children who scored at the threshold for clinical prob-
lems on the attentional problems and/or emotional 
reactivity subscales of the CBCL), data from 1181 healthy 
children (67% of those eligible) were pooled to construct 
the international INTERGROWTH-21st Neurodevel-
opmental Standards. The study sites in Brazil, India, 
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Table 1 Prenatal, perinatal and neonatal characteristics of children who completed the INTER- NDA in the INTERGROWTH-
21st Project compared with those lost to follow- up
Prenatal, perinatal and neonatal characteristics
Children contributing to 
INTERGROWTH-21st international 
INTER- NDA standards (n=1209)
Children lost to 
follow- up (n=331)
Mean (SD) or number (%)
Mean (SD) or 
number (%)
Maternal age at recruitment, years 28.4 (3.8) 27.4 (4.3)
Maternal body- mass- index, kg/m2 23.2 (3.0) 23.6 (2.8)
Multiple gestation n=0 (0.0%) n=0 (0.0%)
Chronic maternal illness n=96 (8.1%) n=26 (7.9)
Maternal infections (including HIV, rubella, syphilis, hepatitis B, 
cytomegalovirus, toxoplasmosis, tuberculosis and malaria)
n=0 (0.0%) n=1 (0.3)
Maternal haemoglobin (g/L) 124.0 (10.0) 124.0 (10.0)
Maternal malignancy n=0 (0.0%) n=0 (0.0%)
Maternal substance abuse (including alcohol) and smoking n=0 (0.0%) n=0 (0.0%)
Maternal use of teratogenic drugs during pregnancy n=628 (53.2) n=222 (67.1%)
Maternal prenatal anxiety and depression/mental stress n=0 (0.0%) n=0 (0.0%)
Maternal preeclampsia and eclampsia n=10 (0.9%) n=4 (1.2%)
Placental structural anomalies n=0 (0.0%) n=0 (0.0%)
Foetal growth restriction n=67 (5.7%) n=14 (4.2)
Gestational age at delivery, weeks* 39.6 (1.2) 39.3 (1.5)
Birth weight, kg* 3.2 (0.4) 3.2 (0.5)
Birth length, cm* 49.2 (1.8) 49.0 (2.1)
Head circumference at birth, cm* 34.0 (1.2) 34.0 (1.3)
Apgar at five min* 9.5 (0.6) 9.6 (0.7)
Age at hospital discharge, days† 3.0 (2.0 to 4.0) 2.0 (1.0 to 3.0)
Boys* n=564 (47.8) n=160 (48.3)
Hyperbilirubinaemia* n=49 (4.1) n=18 (5.5)
Respiratory distress syndrome* n=16 (1.4) n=7 (2.1)
Transient tachypnoea of the newborn* n=11 (0.9) n=12 (3.6)
Exclusive breastfeeding at hospital discharge* n=1097 (93.0) n=300 (90.9)
Data are mean (SD) or number (%) unless otherwise specified.
Missing data below 2% for all variables.
*Mean (SD).
†Median (IQR).
INTER- NDA, INTERGROWTH- 21st Neurodevelopment Assessment.
Italy, Kenya and the UK respectively contributed 147 
(12.2%), 305 (25.2%), 296 (24.5%), 301 (24.9%) and 
160 (13.2%) children to the normative INTER- NDA 
cohort. A detailed description of the prenatal, birth, post-
natal morbidity, growth and nutritional characteristics 
of the cohort, during the first 2 years of life, has previ-
ously been published and is presented in tables 1 and 2.11 
The comparison in sociodemographic, birth, health and 
growth characteristics between the five sites that contrib-
uted to the normative INTER- NDA cohort, and the three 
sites that did not, has also been previously published—
no significant differences were observed between the two 
groups.11
The mean (±SD) age of both girls and boys at assess-
ment was 24.8 (±1.6) months. Eighty- nine per cent of the 
neurodevelopmental measures were obtained between 
22 and 24 months of age, and 99.9% between 22 and 30 
months. The baseline prenatal, perinatal and neonatal 
characteristics were very similar across the five sites,23 and 
with those children lost to follow- up (table 1).
Health, growth and nutritional outcomes from birth to 2 years
The cohort’s mean gestational age and weight at birth 
were 39.6 (±1.2) weeks and 3.2 (±0.4) kg, respectively.11 
The mean birth length and head circumference were 
49.2 (±1.8) cm and 34.0 (+1.3) cm, respectively. Mean age 
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Table 2 Postnatal morbidity between 1 and 2 years of age of children contributing to INTERGROWTH-21st international 
INTER- NDA standards
Morbidity between 1 and 2 years of life
Children contributing to INTERGROWTH-21st 
international INTER- NDA standards
(n=1209)
Hospitalised at least once 113 (9.4)
Total no of days hospitalised* 2 (1–3)
Any prescription provided by a healthcare practitioner 712 (59.1)
  Antibiotics (≥3 regimens) 142 (11.8)
  Iron/folic acid/vitamin B12/other vitamins 194 (16.1)
Up to date with local vaccination policies 1136 (94.4)
Otitis media/pneumonia/bronchiolitis 88 (7.3)
Parasitosis/diarrhoea/vomiting 43 (3.6)
Exanthema/skin disease 150 (12.5)
Urinary tract infection/pyelonephritis 5 (0.4)
Fever ≥3 days (≥3 episodes) 134 (11.1)
Other infections requiring antibiotics 40 (3.3)
Asthma 13 (1.1)
Gastro- oesophageal reflux 3 (0.2)
Cow’s milk protein allergy 8 (0.7)
Food allergies 13 (1.1)
Injury or trauma 27 (2.2)
Any condition requiring surgery 9 (0.7)
Data are number (%) unless otherwise specified.
Missing data below 2% for all variables.
*Median (IQR).
INTER- NDA, INTERGROWTH- 21st Neurodevelopment Assessment.
at discharge from hospital, postbirth, was 3 (2-4) days. 
At hospital discharge, 89% of the cohort was exclusively 
breast milk fed.11 Exclusive breastfeeding was stopped at a 
median of 5 months (IQR, 3–6 months) and (any) breast 
feeding stopped entirely at a median of 12 months (IQR, 
6–18 months). Detailed information on the nutritional 
status of the cohort has been previously published.11
The overall postnatal morbidity of the cohort was low 
(table 2): 9.4% of infants were hospitalised during the 
second year of life with a median hospital stay of 2 days 
(IQR 1–3 days). The most frequently morbidities reported 
in outpatient clinics were exanthema/skin diseases, ≥3 
episodes of fever lasting ≥3 days, and otitis media/lower- 
tract respiratory infections.11 23 At 2 years of age, 92%, 
90% and 91% of the cohort’s length, weight and head 
circumference measures respectively were within the 3rd 
and 97th centiles of the WHO Child Growth Standards.11
Developmental profile of the cohort on independent measures of 
vision and development at 2 years
The visual acuity and contrast sensitivity centiles for our 
cohort are presented in table 3. The cohort’s 50th centile 
values for visual acuity and contrast sensitivity were 0.20 
logMAR and 1.5%, respectively. Both are within the 
Cardiff tests’ normative values for binocular visual acuity 
in children aged 24–30 months.18 The visual acuity and 
contrast sensitivity values were identical for boys and girls 
across all centiles (table 3) suggesting no biological vari-
ability in these outcomes between sexes.
The cohort’s attentional problems and emotional reac-
tivity scores at the 50th centile corresponded to CBCL 
T- scores of 53 and 50, respectively, that is, the 62nd 
and <50th CBCL centiles. These values are below the 
CBCL’s 93rd centile threshold for ‘borderline clinical 
problems’.19 For these CBCL subscales, 28 (2.1%) FGLS 
children scored above the CBCL’s cut- off for clinical 
problems (>97th centile). These children were excluded 
from the INTER- NDA normative sample.
At 2 years of age, the cohort overlapped almost 
perfectly with the WHO motor milestones at the 50th, 
3rd and 97th centiles of the range for healthy term 
infants.11 For length and head circumference, the 
mean+SD z- score was 0.0±1.1 for both measures, and the 
respective medians were at the 49th and 50th percentiles 
of the WHO Child Growth Standards.11 For weight, the 
mean±SD z- score was 0.2±1.1, and median was at the 58th 
percentile. A detailed description of these characteristics 
are presented elsewhere.11
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Table 3 Visual acuity and contrast sensitivity centiles, measured on the Cardiff tests, in the normative sample of the 
International INTER- NDA standards
Pooled centiles (n=1209) Girls (n=628) Boys (n=581) P value
Visual acuity (logMAR)
  c10 0.3 0.3 0.3
  c25 0.2 0.2 0.2
  c50 0.2 0.2 0.2
  c75 0.1 0.1 0.1
  c90 0.1 0.1 0.1
  Median (IQR) 0.2 (0.1–0.2) 0.2 (0.1–0.2) 0.2 (0.1–0.2) 0.463
Contrast sensitivity (%)
  c10 2.0 2.0 2.0
  c25 1.8 1.6 1.9
  c50 1.5 1.5 1.5
  c75 1.0 1.0 1.0
  c90 1.0 1.0 1.0
  Median (IQR) 1.5 (1.0–2.0) 1.5 (1.0–1.5) 1.5 (1.0–2.0) 0.303
*P value from Wilcoxon rank- sum test.
INTER- NDA, INTERGROWTH- 21st Neurodevelopment Assessment.
Table 4 The INTERGROWTH-21st Project international INTER- NDA standards for child development at 2 years of age
INTER- NDA domain
Pooled centiles (n=1181)
c3 c10 c25 c50 c75 c90 c97
Cognitive* 27.4 38.5 62.2 79.5 88.8 92.6 99.6
Fine motor* 17.5 25.7 74.2 91.4 100.0 100.0 100.0
Gross motor* 31.1 51.7 66.7 81.6 100.0 100.0 100.0
Language* 12.1 17.8 45.7 71.7 88.5 95.1 100.0
Positive behaviour* 37.8 51.4 70.0 90.0 100.0 100.0 100.0
Negative behaviour† 0.0 0.0 0.0 25.0 25.0 50.0 76.5
*For these domains, higher scores reflect better outcomes.
†For negative behaviour, lower scores reflect better outcomes.
INTER- NDA, INTERGROWTH- 21st Neurodevelopment Assessment.
International standards for the cognitive, motor, language and 
behaviour domains of the Inter-nDA
The 3rd, 5th, 10th, 50th, 90th, 95th and 97th centiles 
for the INTER- NDA standardised (scaled) scores for 
cognition, language, motor and behaviour domains for 
healthy, well- nourished 2- year- old children are presented, 
in table 4, for the pooled cohort. For all INTER- NDA 
domains, except negative behaviour, higher scores reflect 
better outcomes and the threshold for normality was 
defined as ≥10th centile. For negative behaviour, where 
lower scores reflect better outcomes, the threshold for 
normality was defined as ≤90th centile. The thresholds 
of normality for the INTER- NDA’s cognitive, fine motor, 
gross motor, language and positive behaviour domains 
are ≥38.5, ≥25.7, ≥51.7, ≥17.8 and ≥51.4, respectively. 
The threshold for normality for the INTER- NDA’s nega-
tive behaviour domain is ≤50.0. To facilitate the easy 
and rapid implementation of these standards, in clin-
ical, community and research settings, for the identi-
fication of children scoring ≤10th and ≤3rd centile on 
the INTER- NDA (≥90th and ≥97th centiles for negative 
behaviour) who would benefit from urgent and routine 
further assessment and/or specialist referral, respectively, 
we have developed a neurodevelopmental chart that can 
be printed or downloaded (figure 3).
INTER- NDA domain scores were similar between 
the cohort’s male and female children (online supple-
mentary information S10). There was a trend towards 
higher cognitive and language scores among girls, and 
higher negative behaviour scores among boys (online 
supplementary information S10); however, the clinical 
and developmental implications of these differences are 
unclear.
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Figure 3 The INTERGROWTH-21st Project international INTER- NDA standards for child development at 2 years of age. 
INTER- NDA 3rd to 97th centile ranges for 2- year- old children are presented. These are based on scaled INTER- NDA 
standardised domain scores. Scores falling in the yellow zone correspond to scores between the 10th and 3rd centiles; scores 
in the orange zone correspond to scores <3rd centile. Clinical judgement should determine whether further developmental 
assessment is warranted for children with scores in the yellow and orange zones, and the urgency of such referrals. INTER- 
NDA, INTERGROWTH- 21st Neurodevelopment Assessment.
DIsCussIOn
From this international, population- based cohort of 
optimally healthy and nourished children from Brazil, 
India, Italy, Kenya and the UK (online supplementary 
information S11 and S12); monitored from early preg-
nancy to 2 years of age, we have constructed international 
prescriptive standards for cognitive, language, motor and 
behavioural outcomes in 2- year- old children measured 
on a rapid, comprehensive assessment—the INTER- NDA. 
These centiles were constructed after excluding chil-
dren born at <37 weeks gestation; those with signifi-
cant/neurological morbidity, those whose mothers were 
known to have a mental health diagnoses during preg-
nancy and those who scored above the threshold for 
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clinical attentional and emotional reactivity problems on 
the CBCL. We have confirmed the prenatal, perinatal, 
neonatal and postnatal healthy and well- nourished status 
of the normative INTER- NDA cohort using multiple 
measures during pregnancy, birth, 1 and 2 years of age; 
and have confirmed, at 2 years of age, its low- risk profile or 
adverse neurodevelopmental outcomes.11 The threshold 
of normality for the INTER- NDA’s cognitive, fine motor, 
gross motor, language and positive behaviour domains 
is ≥38.5, ≥25.7, ≥51.7, ≥17.8 and ≥51.4, respectively. The 
threshold for normality for the INTER- NDA’s negative 
behaviour domain is ≤50.0. These centiles represent, to 
our knowledge, the first endeavour to construct standards 
for child developmental outcomes in this age group using 
the WHO prescriptive methodology and an international 
sampling frame. To facilitate the easy and rapid imple-
mentation of these standards in clinical, community and 
research settings for the identification of children at risk 
who would benefit from routine and urgent further assess-
ment and specialist referral, respectively, we have devel-
oped a neurodevelopmental chart that can be printed or 
downloaded (figure 3).
strengths and limitations of this study
The strengths of the IFS Study of the INTERGROWTH-21st 
Project include the population- based cohort design; the 
use of the WHO recommended ‘prescriptive’ approach; 
the international sampling frame; the inclusion of 
rigorous data management, standardisation and quality 
control procedures and the incorporation of indepen-
dent measurements of specific functional and develop-
mental domains (vision, attentional problems, emotional 
reactivity and age of acquisition of key gross motor mile-
stones) to confirm the satisfactory growth, health and 
development of our cohort was confirmed prior to the 
construction of these standards.11 In addition, we used 
the INTER- NDA as the developmental measure of choice 
to construct these standards (table 5). In online supple-
mentary information S1 and S2, we present an overview 
of the normative samples and thresholds for NDDs of 
ten instruments commonly used to measure neurode-
velopmental outcomes in 2- year- old children. Of these, 
two tools (the Guide for Monitoring Child Development, 
GMCD26 27 and the Caregiver- reported Early Develop-
mental Instruments, CREDI28) fulfil some of the WHO- 
based methodological criteria for the construction of 
child developmental standards (GMCD: criteria 1, 3 
and 4; and CREDI: criteria 2 and 4). The INTER- NDA 
fulfils 24 of the 26 criteria. Although a multidimensional 
assessment is easy to implement and was designed for use 
across population groups in high- income, middle- income 
and low- income settings.15 Despite an administration 
time of 15 min, it has demonstrated good to acceptable 
agreement with the BSID- III,16 and can be administered 
reliably, in the field, by trained non- specialists (online 
supplementary information S6).
The main limitation of our study was that the 
INTER- NDA is restricted to the 2- year age group. We 
selected 22–30 months as the time point for the key 
developmental assessment of the entire study because 
developmental markers at this age have been found to 
be predictive of intelligence, school performance, adult 
nutrition and human capital in high- income, middle- 
income and low- income settings29–31; this age also corre-
sponds to the end of Piaget’s sensorimotor stage.32 We 
acknowledge that, while some authors prefer a wider age 
range for population- based child developmental surveil-
lance,3 the second birthday remains the earliest time 
point at which a holistic snapshot of a child’s develop-
mental repertoire can be captured reliably and parsimo-
niously at scale,15 while still within ‘the golden window of 
opportunity for neurodevelopment rescue’—the first 3 
years of life—when interventions are evidenced to yield 
considerable benefits.33 Conversely, some may argue that 
the 22–30 months age range is too broad in the context 
of the rapidly developing nervous system. By evaluating 
the performance of the INTER- NDA against the BSID- III 
in children aged 22–30 months,16 we have provided 
evidence that the INTER- NDA is a valid and reliable 
measure of child development in this age group. Never-
theless, the INTER- NDA is a standardised screening 
assessment and does not provide a clinical diagnosis. 
Therefore, the possibility for misclassification must be 
considered when interpreting the findings. A further 
limitation is that three of the INTERGROWTH-21st 
Project study sites (China, Oman and the USA) did 
not participate in the neurodevelopmental evaluation. 
While the inclusion of these sites might have increased 
our overall sample size; as evidenced by the WHO MGRS 
study, the representation of every country is not neces-
sary for the construction of biological standards because 
of the inherent prescriptive nature of the cohort.6 34 
Our findings, published in 2014 and earlier this year, 
confirmed that the growth and development of children 
across different ancestries, geographies and cultures are 
very similar from early pregnancy to 2 years of age, when 
environmental constraints on their health and nutrition 
are minimal, and justified the pooling of data across the 
five populations for the construction of international 
standards.23 24 An additional limitation of our study is the 
exclusion of the detailed auditory and actigraphy data 
from the analyses.
To address the question as to what limits should be 
applied to determine thresholds of normal and non- 
normal development,12 we were guided by other neuro-
developmental tools using centile ranks to stratify NDD 
risk (online supplementary information S1). While many 
of these define suboptimal development as below the 
25th centile, we have presented evidence that most chil-
dren in our cohort were developmentally normal for age. 
Therefore, we selected a lower threshold (≥10th centile) 
to define neurodevelopmental normality. Nevertheless, 
we acknowledge that, in clinical practice, risk- threshold 
determination may often take into consideration 
other factors such as parental concerns and resource 
allocation.12
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Context of the study
Measuring neurodevelopmental milestones during early 
childhood at scale and comparing outcomes across popu-
lations are essential prerequisites for achieving the United 
Nations Sustainable Development Goal (UN SDG) 4.2 
(‘ensure that all girls and boys have access to quality early 
child development, care and preprimary education so 
that they are ready for primary education’). The interna-
tional INTER- NDA standards presented here contribute 
an important component to the care of young children: 
a unique clinical tool for use across all healthcare systems 
(table 5) to measure neurodevelopmental milestones 
and associated behaviours in 2- year- old uniformly and at 
scale, and to identify children at risk of NDDs who would 
benefit from specialist referral and further investigation 
(figure 3). It is hoped that these INTER- NDA standards, 
complementing our published standards for fetal growth 
and newborn size, and the WHO Child Growth Standards, 
will (1) contribute to the attainment of the early child 
development components of the UN SDGs and the WHO 
survive, thrive, and transform goals of the Global Strategy 
on Women’s, Children’s and Adolescents’ Health and 
(2) provide a methodological template for the extension 
of the construction of child developmental standards to 
younger and older age groups.
COnClusIOn
From this international, population- based cohort of 
healthy and well- nourished children, confirmed to 
be at low- risk of adverse health, growth and develop-
mental outcomes during the first 2 years of life, we have 
constructed the first international standards for cogni-
tion, language, motor skills and behaviour at 2 years of 
age measured on the INTER- NDA. The use of standards 
to measure early child development is superior to refer-
ences because of their prescriptive nature and universal 
applicability, in a manner similar to growth standards.
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